Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2

The development of therapeutics to prevent or treat COVID-19 remains an area of intense focus. Protein biologics, including monoclonal antibodies and nanobodies that neutralize virus, have potential for the treatment of active disease. Here, we have used yeast display of a synthetic nanobody library...

Descripción completa

Detalles Bibliográficos
Autores principales: Pymm, Phillip, Redmond, Samuel J., Dolezal, Olan, Mordant, Francesca, Lopez, Ester, Cooney, James P., Davidson, Kathryn C., Haycroft, Ebene R., Tan, Chee Wah, Seneviratna, Rebecca, Grimley, Samantha L., Purcell, Damian F.J., Kent, Stephen J., Wheatley, Adam K., Wang, Lin-Fa, Leis, Andrew, Glukhova, Alisa, Pellegrini, Marc, Chung, Amy W., Subbarao, Kanta, Uldrich, Adam P., Tham, Wai-Hong, Godfrey, Dale I., Gherardin, Nicholas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529347/
https://www.ncbi.nlm.nih.gov/pubmed/36213007
http://dx.doi.org/10.1016/j.isci.2022.105259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529347/
https://www.ncbi.nlm.nih.gov/pubmed/36213007
http://dx.doi.org/10.1016/j.isci.2022.105259

Ejemplares similares